Q-omics provides the consensus-scored SEPTIN7P12 profile across patient tissues and cancer cell-line models. SEPTIN7P12 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEPTIN7P12 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, SEPTIN7P12 RNA expression shows 8,138 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, STAD, and THYM as cancer lineages where SEPTIN7P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN7P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN7P12 survival associations across molecular data types. SEPTIN7P12 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN7P12 RNA expression–survival associations across cancer types. High SEPTIN7P12 expression shows unfavorable associations in KIRC, DLBC, THYM, UVM and STAD, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEPTIN7P12 RNA expression.
This table summarizes SEPTIN7P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SEPTIN7P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN7P12 shows lower tumor expression in THCA and higher tumor expression in STAD, BRCA, LUAD, COAD and LUSC. The STAD box plot shows higher SEPTIN7P12 RNA expression in tumor versus normal tissue (log2 FC = +0.226, t-test p = .012).
This table shows molecular features associated with SEPTIN7P12 in patient tissues and cancer cell lines. In patient samples, SEPTIN7P12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
